2023 Fiscal Year Final Research Report
Chemoradiotherapy with MMC and UFT for muscle-invasive bladder cancer in elderly patients
| Project/Area Number |
19K08127
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Multi-year Fund |
|---|
| Section | 一般 |
|---|
| Review Section |
Basic Section 52040:Radiological sciences-related
|
|---|
| Research Institution | Iwate Medical University |
|---|
Principal Investigator |
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
菊池 光洋 岩手医科大学, 医学部, 助教 (90758137)
|
|---|
| Project Period (FY) |
2019-04-01 – 2024-03-31
|
| Keywords | 膀胱癌 / 高齢者癌 / 化学放射線療法 / マイトマイシンC / ユーエフティ |
|---|
| Outline of Final Research Achievements |
This study investigated minimally invasive treatment methods for elderly bladder cancer patients who are unsuitable for cystectomy and cisplatin-based chemoradiotherapy. The clinical study using MMC+UFT chemoradiotherapy could not be conducted due to the suspension of MMC supply, and the research funds were returned. A situational survey, including a comparative analysis of patients from university and prefectural hospitals and a multi-institutional questionnaire survey, indicated that non-curative treatments may be frequently chosen for elderly patients outside academic centers. Radiotherapy demonstrated outcomes comparable to or better than surgery in elderly patients, making it a promising option. Currently, a multicenter prospective case registry has been begun together with community hospitals, focusing on hypofractionated radiotherapy to evaluate its efficacy and safety.
|
| Free Research Field |
放射線治療学
|
| Academic Significance and Societal Importance of the Research Achievements |
膀胱癌に対してわが国では保険適応がないMMC+UFTを用いた化学放射線療法について、日本人臨床データが得られれば、学術的・臨床的意義は大きかったが、MMCの供給停止により臨床研究を実施できなかった。
2病院の放射線治療患者数の年次推移から、膀胱癌の治療がアカデミックセンターからコミュニティホスピタルに移行していること、そしてその傾向にCOVID-19パンデミックの影響が見られたことは重要と思われる。高齢者に対する医療の個別化が、安易に非治癒的治療や萎縮医療に繋がらないか注意が必要であり、治癒可能性をもつ放射線治療を高齢者医療に使う意義を生存率データから示せたのは意義があった。
|
